Immunotherapy represents, in fact, one of the great innovations in oncology, since, instead of directly attacking the tumor, these therapies seek to activate the patient's immune system so that it is the patient themselves who recognizes and destroys cancer cells. In the case of CAR-T therapies, T cells are modified in the laboratory to give them the ability to identify and attack cancer with greater precision. In addition, in this area, the Clínic-IDIBAPS teams also work on other innovative strategies, such as therapies with tumor-infiltrating lymphocytes (TILs), which open new avenues for patients who do not respond to conventional treatments.
It is precisely in this type of therapies where the Girem Full! project is framed. With the 352,000 euros raised this year, the initiative will reinforce this line of research at Clínic-IDIBAPS and will contribute to accelerating the development of new treatments against cancer.
Add The New Barcelona Post as your preferred Google source for free
Stay informed with the latest news.